| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
In breast cancer cells, FR054 (0.5–1 mM, 24-48 h) causes an early rise in proliferation, which is followed by a notable decrease in cell viability and an induction of cell display. FR054 inhibits PGM3 instead of having other unintended consequences [1]. (250 μM, 24 hours) therapy has a significant impact on MDA-MB-231 cells' levels of N- and O-glycosylation [1]. ROS-dependent cells and endoplasmic reticulum (ER) mesenchymal cells are induced in cells by FR054 [1].
|
|---|---|
| ln Vivo |
FR054 (1000 mg/kg, intraperitoneal injection) inhibits cancer growth in MDA-MB-231 xenograft mice [1].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: MDA-MB-231 cells. Tested Concentrations: 0.5-1 mM. Incubation Duration: 48 hrs (hours). Experimental Results: Viability was diminished and apoptosis was Dramatically increased compared to control clones. |
| Animal Protocol |
Animal/Disease Models: Mice are injected subcutaneously (sc) (sc) with MDA-MB-231 cells [1].
Doses: 1000 mg/kg. Route of Administration: IP, single or divided doses (500 mg/kg/dose twice (two times) daily). Experimental Results: Twice-daily dosing appeared to have greater in vivo antitumor efficacy compared with single dosing. |
| References |
[1]. Francesca Ricciardiello, et al. Inhibition of the Hexosamine Biosynthetic Pathway by targeting PGM3 causes breast cancer growth arrest and apoptosis. Cell Death Dis. 2018 Mar 7;9(3):377.
|
| Molecular Formula |
C14H19NO8
|
|---|---|
| Molecular Weight |
329.31
|
| Exact Mass |
329.11
|
| Elemental Analysis |
C, 51.06; H, 5.82; N, 4.25; O, 38.87
|
| CAS # |
35954-65-5
|
| Related CAS # |
(6R)-FR054;10378-06-0
|
| SMILES |
CC1=N[C@@]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O2)([H])[C@@]2([H])O1
|
| InChi Key |
WZFQZRLQMXZMJA-KSTCHIGDSA-N
|
| InChi Code |
InChI=1S/C14H19NO8/c1-6-15-11-13(22-9(4)18)12(21-8(3)17)10(5-19-7(2)16)23-14(11)20-6/h10-14H,5H2,1-4H3/t10-,11-,12-,13-,14+/m1/s1
|
| Chemical Name |
5H-Pyrano[3,2-d]oxazole-6,7-diol, 5-[(acetyloxy)methyl]-3a,6,7,7a-tetrahydro-2-methyl-, diacetate (ester), (3aR,5R,6S,7R,7aR)-
|
| Synonyms |
FR054; FR-054; FR 054
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~303.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.59 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.59 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0367 mL | 15.1833 mL | 30.3665 mL | |
| 5 mM | 0.6073 mL | 3.0367 mL | 6.0733 mL | |
| 10 mM | 0.3037 mL | 1.5183 mL | 3.0367 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
